2024 M&A Year in Review - Flipbook - Page 34
34
Life Sciences
and Health Care
Sector performance
In 2024, M&A in the life sciences and health care sector
experienced a decline in both volume and value. While the
industry experienced a steady flow of midmarket transactions,
there were significantly fewer megadeals than in 2023.
The sector remained focused on innovation, particularly
in digital health and artificial intelligence, to enhance
precision diagnostic tools and drug discovery and
development. Additionally, companies continued to use
milestones and earnouts to address valuation challenges
in transactions.
Hogan Lovells activities
Our Life Sciences and Health Care team hosted events
and produced podcasts to help clients stay ahead of
industry trends.
We released our annual Life Sciences and Health Care Horizons
publication, providing an analysis of key considerations for
companion diagnostic collaborations, among other forwardlooking transaction topics. We continued to share insights
into opportunities and challenges in the sector through our
Talking the Cure podcast series and launched a new series:
Pharma – The Last Word.
Hogan Lovells
is one of the
best life sciences
teams. They
combine a depth
of experience…
with an energy
and working style
that clients
love, achieving
great results.”
Chambers Global, 2024
